|
08:45
|
Registration, coffee & networking
|
|
09:15
|
Chairman’s welcome
Koos Oosterhaven, Nizo, The Netherlands
|
|
09:25
|
How the microbiome revolution fuels functional food research – practical examples and prospects
Dr Nathalie Delzenne, Head of Research Group in Metabolism & Nutrition, Louvain Drug Research Institute, Belgium
|
|
09:55
|
Intestinal barrier dysfunction, probiotic supplementation and sports performance
Dr Manfred Lamprecht, Adj, Professor, Centre for Physiological Medicine, Medical University of Graz & Director, Green Beat, Institute of Nutrient Research and Sport Nutrition, Austria
|
|
10:25
|
Coffee & networking break
|
|
|
PROBIOTECH Stream 3.1: New advances and regulatory challenges
|
PROBIOTECH Stream 3.2: Application Exchange
|
|
11:05
|
Latest in synbiotics
Dr Karen Scott, University of Aberdeen, UK
|
Lessons from animal nutrition
Dr Simon Davies, Plymouth University, UK
|
|
11:30
|
Challenging the “strain-specificity” dogma in a new approach to regulators
A considered look at the clinical evidence for probiotics reveals a new way of thinking.
- Probiotic strains can have unique characteristics and functions
- However, some strains share a lot in common and elicit the same health benefit
- It’s time to think differently about evaluating the probiotic evidence
Ross Crittenden, Chairman of Global Alliance for Probiotics (GAP)
|
Antimicrobial production by LAB applied to general food safety and food security
Professor Thomas Montville, Rutgers University, USA
|
|
11:55 |
The Italian connection: Italy goes its own way
- Has Italy found a way around the regulations?
- Can its actions be applied elsewhere?
Sebastian Romero Melchor, K&L Gates, Brussels
|
Functional opportunities for next generation probiotics and challenges for their protected delivery
- Screening of candidate probiotic strains should look beyond the conventional lactic acid producing bacteria
- Bacteriotherapy with entire populations is gaining momentum in the clinical field
- Delivery of next generation probiotics may require the design of more product-specific delivery techniques
Professor Tom Van de Wiele, The Laboratory of Microbial Ecology and Technology, Belgium
|
|
12:20
|
How a low GI prebiotic ingredient could be a long lasting source of energy
- How the fate of a prebiotic in the gut might explain a long lasting production of energy
- How the gut microbiota might play a role in this context
Dr Sophie Chesnoy, Roquette, France
|
Gut Organoids: Development of a Novel stem cell based screening platform for gut-microbiota interactions
Dr Sabina Lukovac, Innovation Scientist, TNO, The Netherlands
|
|
12:45
|
Lunch
|
|
14:00
|
Evolving trial design: does EFSA matter?
- Are EFSA's protocols relevant to academia?
- Is academic research useful to commerce anymore?
- How will trials look in five years' time?
Murielle Cazaubiel, Head of Biofortis Clinical, France
|
|
14:25
|
Breaking the EU law: 200+ probiotic rejections reach Article 13.1 law books. Now what?
- What can be claimed and where
- Product design
- Websites
- Is 'probiotic' an implied health claim?
- Soiling the grey list
Jean Savigny, Senior Partner, Keller & Heckman, Brussels
|
|
14:50
|
Panel discussion: Regulation
|
|
15:15
|
Closing remarks
|
|
15:30
|
End of conference
|
